Pharmacogenomics aims to use molecular genetic markers to predict treatment outcome. Indeed, within the past decade there has been a rapid emergence of pharmacogenetic tests to aid clinicians in predicting efficacy or toxicity for some drugs. Despite this major advance in therapeutic drug management, there remain challenges to the appropriate use of pharmacogenetic tests. We discuss UGT1A1 pharmacogenetic testing to illustrate the knowledge gaps impeding widespread use of pharmacogenetic tests in the clinical setting.
Pharmacogenetic tests are potentially useful tools for making a therapeutic decision by identifying patients who should or should not receive a particular drug, as well as for guiding individual drug dosing. Pharmacogenetic test information is currently included in more than 200 drug labels in the United States. 1 The information is classified into three categories that guide the clinical use of pharmacogenetic tests for reaching a therapeutic decision 2 : (i) test required, (ii) test recommended, and (iii) for information only (Table 1) . Thus far, only four drugs-cetuximab, trastuzumab, maraviroc, and dasatinibrequire a pharmacogenetic test before they are prescribed; the majority of drugs with labels containing pharmacogenetic test information do not require such testing. For example, the label for the anticancer drug irinotecan recommends testing for the presence of a variant of UDP-glucuronosyl transferase 1A1 (UGT1A1) to prevent drug toxicity. However, pharmacogenetic testing for UGT1A1, like most pharmacogenetic tests, has many challenges for its appropriate clinical use. In this article, we use the UGT1A1 pharmacogenetic test as an example to illustrate some of the major challenges to the clinical application of pharmacogenetic tests: incomplete knowledge of the extent of human genetic variation, availability of alternative biomarkers, and the lack of a model of delivery for pharmacogenetic information.
UGT1A1 pharmacogenetic testing
UGT1A1 is a hepatic enzyme involved in the glucuronidation of bilirubin and many drugs, such as the active metabolite of the anticancer drug irinotecan. Its enzymatic activity differs among individuals and can be indirectly affected by environmental, physiological, and epigenetic changes. However, UGT1A1 enzyme function is genetically determined by inherited sequence variation in the coding and noncoding regions, most notably a two-base-pair insertion (TA) n in its promoter region. 3 The most common promoter variants are (TA) 5 , (TA) 6 , (TA) 7 , and (TA) 8 (ref. 3) . The (TA) 5 and (TA) 6 variants are associated with high UGT enzymatic activity; the (TA) 6 allele, in particular, is referred to as the *1 or wild-type allele. The (TA) 7 and (TA) 8 repeats are associated with low UGT enzymatic activity. 3 For the purposes of this article, we focus on the variant (TA) 7 , or *28, allele because it has received the most attention.
The *28 allele is associated with inherited forms of unconjugated hyperbilirubinemia such as Gilbert syndrome and Crigler-Najjar syndrome. 4 With regard to drug therapy, retrospective and prospective studies have demonstrated an association between the presence of reduced UGT1A1 enzymatic activity (especially with the *28 allele) and increased incidence of toxicity, most notably severe neutropenia in patients treated with irinotecan. 5, 6 The association between the *28 allele and severe diarrhea is not as statistically significant as is the association with neutropenia. Therefore, there may be other, yet unknown genetic factors that are more predictive of irinotecan-induced diarrhea. In 2005, the US Food and Drug Administration (FDA) amended the package insert for irinotecan to include a recommendation, but not a requirement, to test for the *28 UGT1A1 variant to predict those at risk for neutropenia. 7 Shortly thereafter, the Invader Molecular assay for UGT1A1 genotyping appeared on the market as an FDA-approved test, with an overall correct-call rate of 98.8%. 8 A recent meta-analysis reported that the risk of severe neutropenia for patients homozygous for the *28 allele may be a function of the administered dose of irinotecan. 9 The study found that the risk of toxicity was higher for patients homozygous for *28 who were on chemotherapeutic regimens of irinotecan (alone or in combination with other myelotoxic drugs) involving a moderate dose (150-250 mg/m 2 , odds ratio (OR) = 3.22, 95% confidence interval (CI) = 1.52-6.81; P = 0.008) or a high dose of irinotecan (>250 mg/m 2 , OR = 27.8, 95% CI =4.0-195; P = 0.005) as compared with patients heterozygous for *28 and homozygous for *1 (wild type). 9 For this reason, the study's authors have asserted, contrary to the perspec tives UGT1A1 test into their clinical practice. It is unknown, however, how knowledge of the genotype influenced their care of patients. 8 On the other hand, there are others who did not heed the FDA's recommendation for UGT1A1 genotyping, in part because of the uncertainty of its clinical utility. What, then, are the challenges to the use of pharmacogenetic testing for UGT1A1 in the clinic? of irinotecan. However, recent reports show that a decrease in irinotecan dose for patients homozygous for the *28 allele may result in decreased tumor response, further complicating determination of appropriate drug dose to prevent irinotecan toxicity. 8 In light of the FDA's initial recommendation, oncologists at several academic health centers incorporated the FDA's initial recommendation of a dose reduction based on genotype alone, that a reduced irinotecan dose or an alternative treatment regimen be used only when the *28 allele is present and a high-dose irinotecan regimen is prescribed. 9 This recent finding may help refine the FDA labeling of irinotecan as it pertains to the interpretation of the UGT1A1 genotype within the context of appropriate dosing 9 Such data would be very useful if third-party payers are to shoulder the cost of pharmacogenomic testing.
Third, successful integration of pharma cogenetic testing in the clinic requires not only a clinical laboratory that establishes and validates the assay but also a rapid reporting system that provides appropriate guidance about the interpretation of the test results. Given the complexity of the process, it will probably require the coordinated efforts of multiple health-care professionals, including laboratory medicine specialists, physicians, nurses, and pharmacists.
Finally, clinicians' knowledge of pharmacogenetic testing may also influence its successful integration into the clinic. A recent systematic review suggests that clinicians are not generally confident in providing genetic services to patients because of lack of training and knowledge. 10 Therefore, efforts are needed to improve clinicians' knowledge of pharmaco genetic tests in order to facilitate their successful integration into clinical practice.
Third, there is no model for the delivery and interpretation of the UGT1A1 test. In the modified label for irinotecan, the FDA recommends a reduced initial dose of irinotecan for patients homozygous for the *28 allele. The FDA recommendations go on to state, however, that the precise dose reduction in patients homozygous for the *28 allele is unknown and that subsequent dose modifications should be tailored according to an individual patient's treatment tolerance. 7 Unlike other genetic tests for disease prognosis, the reports for pharmacogenetic tests are currently not interpreted for the ordering physicians. There is neither a detailed explanation of how and to what extent the initial dose should be reduced, nor instructions on how long the patient should remain on the reduced dose. The onus is on the ordering oncologist to consult with other colleagues and the literature to make sense of how to use the test result to manage irinotecan dosing. Without clear instructions on how to interpret and use the test results, oncologists, who are generally not trained in interpreting genetic tests, may be reluctant to order the test in the first place.
Discussion
Given the challenges for the appropriate use of the UGT1A1 pharmacogenetic test, it is clear that considerably more clarification of the role of the UGT1A1 test in the management of irinotecan toxicity is necessary. Importantly, these challenges are not unique to the UGT1A1 test, and therefore solutions to redress knowledge gaps in the use of UGT1A1 testing can be extended to other pharmaco genetic tests. First, pharmacogenetic tests could be more clinically applicable if they included a comprehensive survey of variation in the human genome. Many current pharmacogenetic tests evaluate one or a few candidate genes with a biologically plausible link to drug responses. Although successful for some drugs, this approach may miss important contributions of variation in other genes, thereby reducing the predictive value of the test. It is promising that many recent pharmacogenomic studies use a genome-wide approach. In addiThe first challenge is that the UGT1A1 test may be limited in its general applicability in diverse populations. There are at least 113 variants of the UGT1A1 gene, most of which are associated with reduced or inactive enzyme activity; a few are associated with increased activity, and still others are of unknown significance. 4 However, the most widely used UGT1A1 test (the Invader Molecular Assay) assesses only one promoter variant, the *28 allele. Homozygosity for the *28 allele occurs in 10% of the North American population and at a similar frequency in Caucasians and African Americans but a lower frequency in Asians. 4 The frequency of the *28 allele has not been thoroughly studied in other ethnic groups, such as Hispanics living in North America. Even if one were to comprehensively test for all the known genotypes of the UGT1A1 promoter polymorphisms, the mere fact that only that portion of the gene is assessed and not the entire gene sequence will mean that other potentially important variants are missed, variants that may have an impact on clinical care. For example, the currently FDA-approved UGT1A1 test does not include the reduced-activity *6 allele in the coding region (211G→A, G71R), which is less common than the *28 allele but has been shown to be predictive of hyperbilirubinemia, especially in Asians. 4 Second, an inexpensive biomarker, total serum bilirubin, is available as a clinical predictor of liver function and can serve as a surrogate marker of UGT1A1 enzyme function and severe neutropenia before administering irinotecan. 6 Some oncologists argue against the use of the UGT1A1 genotype because they think bilirubin levels, with which they are more comfortable, may be as reliable an indicator as the genotype in predicting the appropriate irinotecan dose (anecdotal evidence). However, there are no studies showing how total bilirubin levels may be used to guide irinotecan dose modification or a priori selection. Thus, a second challenge is uncertainty over the clinical utility of UGT1A1 genotype and serum bilirubin in guiding the appropriate dose selection for irinotecan.
